Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
Objectives: The objective of this review was to examine the latest literature regarding the effectiveness of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient populations. Methods: Literature review of published real-world and randomized control trials (RCTs) from 2...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223006458 |
| _version_ | 1827875742898192384 |
|---|---|
| author | Juthaporn Cowan Ashley Amson Anna Christofides Zain Chagla |
| author_facet | Juthaporn Cowan Ashley Amson Anna Christofides Zain Chagla |
| author_sort | Juthaporn Cowan |
| collection | DOAJ |
| description | Objectives: The objective of this review was to examine the latest literature regarding the effectiveness of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient populations. Methods: Literature review of published real-world and randomized control trials (RCTs) from 2020 to May 2023. Results: COVID-19 is highly transmissible with potentially serious health outcomes, underscoring the need for effective prevention and treatment strategies. Vaccines are highly effective at preventing COVID-19 for the general population; however, efficacy is often impaired in immunocompromised patients given insufficient response to initial exposure and/or memory for secondary exposures. Some individuals may also have contraindications to vaccination. As such, additional protective measures are needed to bolster the immune response in these populations. Monoclonal antibodies have been effective at bolstering immune system responses to COVID-19 among immunocompromised patients; however, they are proving ineffective against the most recent Omicron strains (BA.4 and BA.5). Conclusion: Several studies have investigated the efficacy of monoclonal antibodies as pre- and post-prophylaxis for COVID-19. Historical evidence is promising; however, new variants of concern are proving challenging for currently available regimens. |
| first_indexed | 2024-03-12T17:12:22Z |
| format | Article |
| id | doaj.art-6f1cce3ef5b34738bfb40d8ca9aec380 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-12T17:12:22Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-6f1cce3ef5b34738bfb40d8ca9aec3802023-08-06T04:36:46ZengElsevierInternational Journal of Infectious Diseases1201-97122023-09-01134228238Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populationsJuthaporn Cowan0Ashley Amson1Anna Christofides2Zain Chagla3Department of Medicine, Division of Infectious Diseases, University of Ottawa, The Ottawa Hospital, 501 Smyth Road, Ontario K1H 8L6 Ottawa, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ontario K1H 8L6, Ottawa, Canada; Centre for Infection, Immunity and Inflammation, Ontario K1H 8M5 Ottawa, Canada; Corresponding author:IMPACT Medicom Inc., Ontario M6S 3K2, Toronto, CanadaIMPACT Medicom Inc., Ontario M6S 3K2, Toronto, CanadaDepartment of Medicine, McMaster University, and St. Joseph's Healthcare, Ontario L8N 4A6, Hamilton, CanadaObjectives: The objective of this review was to examine the latest literature regarding the effectiveness of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient populations. Methods: Literature review of published real-world and randomized control trials (RCTs) from 2020 to May 2023. Results: COVID-19 is highly transmissible with potentially serious health outcomes, underscoring the need for effective prevention and treatment strategies. Vaccines are highly effective at preventing COVID-19 for the general population; however, efficacy is often impaired in immunocompromised patients given insufficient response to initial exposure and/or memory for secondary exposures. Some individuals may also have contraindications to vaccination. As such, additional protective measures are needed to bolster the immune response in these populations. Monoclonal antibodies have been effective at bolstering immune system responses to COVID-19 among immunocompromised patients; however, they are proving ineffective against the most recent Omicron strains (BA.4 and BA.5). Conclusion: Several studies have investigated the efficacy of monoclonal antibodies as pre- and post-prophylaxis for COVID-19. Historical evidence is promising; however, new variants of concern are proving challenging for currently available regimens.http://www.sciencedirect.com/science/article/pii/S1201971223006458Monoclonal antibodyProphylaxisCOVID-19Immunocompromised population |
| spellingShingle | Juthaporn Cowan Ashley Amson Anna Christofides Zain Chagla Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations International Journal of Infectious Diseases Monoclonal antibody Prophylaxis COVID-19 Immunocompromised population |
| title | Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations |
| title_full | Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations |
| title_fullStr | Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations |
| title_full_unstemmed | Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations |
| title_short | Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations |
| title_sort | monoclonal antibodies as covid 19 prophylaxis therapy in immunocompromised patient populations |
| topic | Monoclonal antibody Prophylaxis COVID-19 Immunocompromised population |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223006458 |
| work_keys_str_mv | AT juthaporncowan monoclonalantibodiesascovid19prophylaxistherapyinimmunocompromisedpatientpopulations AT ashleyamson monoclonalantibodiesascovid19prophylaxistherapyinimmunocompromisedpatientpopulations AT annachristofides monoclonalantibodiesascovid19prophylaxistherapyinimmunocompromisedpatientpopulations AT zainchagla monoclonalantibodiesascovid19prophylaxistherapyinimmunocompromisedpatientpopulations |